Short answer
Korro Bio, Inc. (KRRO) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 (down 100.0% year over year) with net income of −$18M.
Q3 2026 key financials · XBRL
- Revenue
- $0
- −100.0% YoY
- Net income
- −$18M
- +2.8% YoY · +7.2% QoQ
- EPS (diluted)
- −$0.93
- +51.6% YoY · +2.1% QoQ
Source: XBRL data from the Korro Bio, Inc. (KRRO) Q3 2026 10-Q on SEC EDGAR. USD.
Korro Bio, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly collaboration revenue $0.0M, down $1.1M YoY
- Net loss $17.5M vs $18.1M YoY, operating loss $18.5M vs $19.2M
- KRRO-121 R&D $2.2M, up $1.9M YoY, strongest disclosed program growth
- KRRO-110 R&D down $3.6M following REWRITE trial termination, weakest disclosed program
- Cash $124.8M, operating cash outflow $46.0M, $85.3M financing inflow, runway into second half of 2028
Risk Factors
- Newly intensified healthcare regulation: CMS finalized GLOBE in September 2026, with Medicare Part B implementation scheduled for January 1, 2027
- Most material clinical risk: KRRO-121 remains tested only in limited healthy volunteers, with no UCD or HE patient data
- Regulatory risk: FDA has not reviewed ANCHOR under an IND, and Part 2 requires regulatory approval
- Operational risk: UCD rarity and specialized metabolic centers could delay ANCHOR Part 2 enrollment and the second-half 2027 interim readout
- Financial risk: $124.8 million in cash, equivalents and marketable securities funds operations only into the second half of 2028, without committed additional capital
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Korro Bio, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.